Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus johnsonii is a probiotic bacterium that has been investigated for its potential benefits in gastrointestinal disorders, including Irritable Bowel Syndrome (IBS). The scientific evidence supporting its use in IBS is limited but exists. Several small-scale clinical studies and animal experiments suggest that L. johnsonii may help modulate gut microbiota, reduce intestinal inflammation, and enhance the gut barrier function. For instance, some randomized controlled trials have shown modest improvements in symptoms such as bloating, abdominal pain, and stool frequency in IBS patients who received supplements containing L. johnsonii. Mechanistically, the strain is thought to influence immune responses and alter the composition of gut flora, which may be beneficial in IBS, a condition associated with dysbiosis and low-grade inflammation.

However, the body of evidence is not robust. Most studies have small sample sizes, and findings are sometimes inconsistent. Additionally, many commercial probiotic formulations contain L. johnsonii in combination with other strains, making it difficult to isolate its specific effects. Major clinical guidelines do not currently recommend L. johnsonii as a first-line therapy for IBS due to insufficient high-quality evidence. More large, well-designed clinical trials are needed to clarify its efficacy. In summary, while there is some preliminary scientific support for L. johnsonii in IBS, the overall evidence base is weak and does not yet warrant strong recommendations for clinical use.

More about Lactobacillus johnsonii
More about Irritable Bowel Syndrome

Other ingredients used for Irritable Bowel Syndrome

Other health conditions supported by Lactobacillus johnsonii

Products containing Lactobacillus johnsonii